Celgene

Abecma

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Celgene

Abecma HCPCS:

Q2055

HCPCS Code Descriptor:

Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

Abecma NDCs:

59572-0515-02, 59572-0515-03, 59572-0515-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Bag

Route of Administration:

Intravenous

Abecma CPT Codes:

Potential CPT administration codes for Abecma can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Abecma:

Abecma is an Oncology drug manufactured by Celgene and administered via the Intravenous route of administration. The Q Code: Q2055 is aligned to the drug Abecma.

ACCESS PRICING AND MORE BY REGISTERING

Q2055 Added Date:

January 1, 2022

Q2055 Effective Date:

January 1, 2022

Q2055 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Abecma billing and coding information.
Abecma patient assistance information can be found through Cell Therapy 360 at the URL: https://www.celltherapy360.com/patients/
Abecma prescribing information can be found at the link below:
Information regarding Abecma’s side effects can be found at MedlinePlus